Multiple resistant Pseudomonas aeruginosa in contemporary medical practice: findings from urinary isolates at a Nigerian University Teaching Hospital.
Pseudomonas aeruginosa is a bacterium that is often encountered in urinary tract infection (UTI) worldwide and has shown varied antibiotic susceptibility patterns. This study was therefore designed to ascertain the antibiotic susceptibility patterns of the organism in Jos. Data on antimicrobial susceptibility of P. aeruginosa generated from urine samples by the Microbiology laboratory of Jos University Teaching Hospital (JUTH) was compiled for a period of three years (July 2001-June 2004). Additional information was obtained from the records department of the hospital. Samples were collected, stored and processed using standard laboratory procedures. The rate of isolation of P. aeruginosa from urine samples was found to be 4.6% (n=127) from 12,458 samples. From male population 34% (n=43) were isolated and 66 % (n=84) were recovered from females population with a significant (P < 0.05) gender difference. All the 100 % isolates of P. aeruginosa were resistant to penicillin, cloxacillin, tetracycline, nitrofurantoin and nalidixic acid. while 67% were sensitive to augmentin, sensitivity to ofloxacin was 92%, ciprofloxacin 92% and cefuroxime (86%). The resistance pattern of P. aeruginosa from urine against antibiotics was extremely high. Prophylactic antibiotic medication against UTI should be carefully weighed against this undesirable possible outcome (resistance). Susceptibility testing should be adopted as a basic routine laboratory procedure in hospitals and clinics in order to guide appropriately on the right choice of antibiotics. Finally, ofloxacin, ciprofloxacin, and cefuroxime should be considered on isolation of P. aeruginosa from UTI, especially in the absence of a sensitivity report as well as for prophylactic options.
Jombo
G T A
GT
Department of Medical Microbiology and Parasitology, College of Medical Sciences, University of Calabar, Calabar, Nigeria. jombogodwin@yahoo.com
Jonah
P
P
Ayeni
J A
JA
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009549:Nigeria / Q000453:epidemiology; D018579:Patient Selection; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D014556:Urine / Q000382:microbiology
D000900:Anti-Bacterial Agents